PRESTIGE_MEDICAL_LIMITED - Accounts


Company registration number 02826793 (England and Wales)
PRESTIGE MEDICAL LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2022
PRESTIGE MEDICAL LIMITED
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 12
PRESTIGE MEDICAL LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2022
31 December 2022
- 1 -
31 December
30 November
2022
2021
Notes
£
£
£
£
Fixed assets
Intangible assets
3
4,572
8,447
Tangible fixed assets
4
512,947
521,432
517,519
529,879
Current assets
Stocks
5
879,154
589,102
Debtors
6
736,525
755,437
Cash at bank and in hand
57,962
172,172
1,673,641
1,516,711
Creditors: amounts falling due within one year
7
(2,499,724)
(1,874,357)
Net current liabilities
(826,083)
(357,646)
Total assets less current liabilities
(308,564)
172,233
Creditors: amounts falling due after more than one year
7
(387,008)
(422,930)
Net liabilities
(695,572)
(250,697)
Capital and reserves
Called up share capital
12
6,500,002
6,500,002
Profit and loss reserves
(7,195,574)
(6,750,699)
Total equity
(695,572)
(250,697)

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 19 May 2023 and are signed on its behalf by:
Mr J S Potter
Director
Company registration number 02826793
PRESTIGE MEDICAL LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 31 DECEMBER 2022
- 2 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 December 2020
6,500,002
(6,604,892)
(104,890)
Year ended 30 November 2021:
Loss and total comprehensive income for the year
-
(145,807)
(145,807)
Balance at 30 November 2021
6,500,002
(6,750,699)
(250,697)
Period ended 31 December 2022:
Loss and total comprehensive income for the period
-
(444,875)
(444,875)
Balance at 31 December 2022
6,500,002
(7,195,574)
(695,572)
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2022
- 3 -
1
Accounting policies
Company information

Prestige Medical Limited is a private company limited by shares incorporated in England and Wales. The registered office is East House, Duttons Way, Shadworth Business Park, Blackburn, BB1 2QR.

1.1
Reporting period

These financial statements have been prepared for the 13 month period from 1 December 2021 to 31 December 2022. The financial year end was extended in order to align with the parent company year end.

1.2
Accounting convention

The financial statements have been prepared in accordance with Financial Reporting Standard 101 Reduced Disclosure Framework (FRS 101) and in accordance with applicable accounting standards.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

As permitted by FRS 101, the company has taken advantage of the following disclosure exemptions from the requirements of IFRS:

  • presentation of a statement of cash flows and related notes;

  • disclosure of the categories of financial instrument and the nature and extent of risks arising on these financial instruments;

  • the effect of financial instruments on the statement of comprehensive income;

  • comparative period reconciliations for the number of shares outstanding and the carrying amounts of property, plant and equipment, intangible assets, investment property and biological assets;

  • disclosure of the future impact of new International Financial Reporting Standards in issue but not yet effective at the reporting date;

  • related party disclosures for transactions with the parent or wholly owned members of the group.

The financial statements of the company are consolidated in the group accounts of Tuttnauer Limited. The group accounts of Tuttnauer Limited are available to the public and are available from its registered office.

1.3
Going concern

The company is reliant upon support from its trueparent and group companies. The directors have, at the time of approving the financial statements, a reasonable expectation that the company has adequate resources, supported by its parent company, to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements.

 

In arriving at this assessment the directors have obtained assurance from its parent company that support will continue to be provided as is appropriate by the parent and group and that no support provided to date by the parent and group will be withdrawn.

 

Although the company is showing a net liability and net current liability position as at 31 December 2022, £1,177k of the companies liabilities are owed to group companies and are not subject to fixed repayment schedules. The company is fully owned by the Tuttnauer Group which continues to support the company.

 

In light of the above the directors consider that there are no material uncertainties that lead to a significant doubt upon the company's ability to continue as a going concern. The directors have relied on the ongoing support of the parent group in making their assessment.

 

PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2022
1
Accounting policies
(Continued)
- 4 -
1.4
Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the company and the turnover can be reasonably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

 

The company does not expect to have any contracts where the period between the transfer of the promised good or services to the customer and payment by the customer exceeds one year. As a consequence, the company does not adjust any of the transaction prices for the time value of money.

 

Turnover from providing services is recognised in the accounting period in which the services are rendered.

 

Revenue of a standalone service is recognised at a point in time when the service is completed.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.5
Intangible assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

 

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

  • Software: 3 to 5 years

  • Website: 3 years

1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Right-of-use leasehold property
10 years
Right-of-use other assets
5 to 7 years
Plant and equipment
3 to 15 years
Right-of-use motor vehicles
3 years

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.

1.7
Impairment of tangible and intangible assets

At each reporting end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2022
1
Accounting policies
(Continued)
- 5 -

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

 

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.8
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit and loss. Reversals of impairment losses are also recognised in profit or loss.

1.9
Cash at bank and in hand

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10
Financial assets

Financial assets are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument. Financial assets are classified into specified categories, depending on the nature and purpose of the financial assets.

 

At initial recognition, financial assets classified as fair value through profit and loss are measured at fair value and any transaction costs are recognised in profit or loss. Financial assets not classified as fair value through profit and loss are initially measured at fair value plus transaction costs.

Financial assets held at amortised cost

Financial instruments are classified as financial assets measured at amortised cost where the objective is to hold these assets in order to collect contractual cash flows, and the contractual cash flows are solely payments of principal and interest. They arise principally from the provision of goods and services to customers (eg trade receivables). They are initially recognised at fair value plus transaction costs directly attributable to their acquisition or issue, and are subsequently carried at amortised cost using the effective interest rate method, less provision for impairment where necessary. Financial assets classified as receivable within one year are not amortised.

PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2022
1
Accounting policies
(Continued)
- 6 -
1.11
Financial liabilities

The company recognises financial debt when the company becomes a party to the contractual provisions of the instruments. Financial liabilities are classified as either 'financial liabilities at fair value through profit or loss' or 'other financial liabilities'.

Other financial liabilities

Other financial liabilities, including borrowings, trade payables and other short-term monetary liabilities, are initially measured at fair value net of transaction costs directly attributable to the issuance of the financial liability. They are subsequently measured at amortised cost using the effective interest method. For the purposes of each financial liability, interest expense includes initial transaction costs and any premium payable on redemption, as well as any interest or coupon payable while the liability is outstanding. Financial liabilities classified as payable within one year are not amortised.

1.12
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.13
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax is the tax expected to be payable or recoverable on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.14
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of inventories or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2022
1
Accounting policies
(Continued)
- 7 -
1.15
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.16
Leases

At inception, the company assesses whether a contract is, or contains, a lease within the scope of IFRS 16. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Where a tangible asset is acquired through a lease, the company recognises a right-of-use asset and a lease liability at the lease commencement date. Right-of-use assets are included within tangible fixed assets, apart from those that meet the definition of investment property.

The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date plus any initial direct costs and an estimate of the cost of obligations to dismantle, remove, refurbish or restore the underlying asset and the site on which it is located, less any lease incentives received.

 

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of other tangible fixed assets. The right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are unpaid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the company's incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise fixed payments, variable lease payments that depend on an index or a rate, amounts expected to be payable under a residual value guarantee, and the cost of any options that the company is reasonably certain to exercise, such as the exercise price under a purchase option, lease payments in an optional renewal period, or penalties for early termination of a lease.

The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in: future lease payments arising from a change in an index or rate; the company's estimate of the amount expected to be payable under a residual value guarantee; or the company's assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.

2
Employees

The average monthly number of persons (including directors) employed by the company during the period was:

2022
2021
Number
Number
39
38
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2022
- 8 -
3
Intangible fixed assets
Software
Development costs
Website
Total
£
£
£
£
Cost
At 30 November 2021
123,468
-
0
51,631
175,099
At 31 December 2022
123,468
-
0
51,631
175,099
Amortisation and impairment
At 30 November 2021
118,093
-
0
48,559
166,652
Charge for the year
1,474
-
0
2,401
3,875
At 31 December 2022
119,567
-
0
50,960
170,527
Carrying amount
At 31 December 2022
3,901
-
0
671
4,572
At 30 November 2021
5,375
-
0
3,072
8,447
4
Tangible fixed assets
Right-of-use leasehold property
Plant and equipment
Right-of-use other assets
Right-of-use motor vehicles
Total
£
£
£
£
£
Cost
At 1 December 2021
537,962
2,061,887
15,093
104,608
2,719,550
Additions
-
0
21,336
-
0
100,604
121,940
Disposals
-
0
(1,097,249)
-
0
(11,326)
(1,108,575)
At 31 December 2022
537,962
985,974
15,093
193,886
1,732,915
Accumulated depreciation and impairment
At 1 December 2021
114,258
2,036,016
7,384
40,460
2,198,118
Charge for the period
61,889
15,058
4,080
46,779
127,806
Eliminated on disposal
-
0
(1,094,630)
-
0
(11,326)
(1,105,956)
At 31 December 2022
176,147
956,444
11,464
75,913
1,219,968
Carrying amount
At 31 December 2022
361,815
29,530
3,629
117,973
512,947
At 30 November 2021
423,704
25,871
7,709
64,148
521,432
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2022
- 9 -
5
Stocks
2022
2021
£
£
Raw materials
538,451
383,973
Finished goods
340,703
205,129
879,154
589,102
6
Debtors
Due within one year
Due after one year
2022
2021
2022
2021
£
£
£
£
Trade debtors
393,639
493,441
-
-
Provision for bad and doubtful debts
(16,710)
(40,000)
-
-
376,929
453,441
-
-
Amounts owed by fellow group undertakings
4,802
-
0
-
0
-
0
Other debtors
1,692
19,210
-
-
Prepayments and accrued income
40,322
32,809
-
-
423,745
505,460
-
-
Deferred tax asset
-
-
312,780
249,977
423,745
505,460
312,780
249,977
7
Creditors
Due within one year
Due after one year
2022
2021
2022
2021
Notes
£
£
£
£
Creditors
8
2,241,428
1,524,962
-
0
-
0
Taxation and social security
142,195
266,029
-
-
Lease liabilities
9
116,101
83,366
387,008
422,930
2,499,724
1,874,357
387,008
422,930
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2022
- 10 -
8
Creditors
2022
2021
£
£
Trade creditors
555,128
268,734
Amount owed to parent undertaking
1,054,697
-
0
Amounts owed to fellow group undertakings
121,969
851,662
Accruals and deferred income
509,454
404,386
Other creditors
180
180
2,241,428
1,524,962
9
Lease liabilities
2022
2021
Maturity analysis
£
£
Within one year
116,101
83,366
In two to five years
326,003
316,633
In over five years
61,005
106,297
Total undiscounted liabilities
503,109
506,296

Lease liabilities are classified based on the amounts that are expected to be settled within the next 12 months and after more than 12 months from the reporting date, as follows:

2022
2021
£
£
Current liabilities
116,101
83,366
Non-current liabilities
387,008
422,930
503,109
506,296
2022
2021
Amounts recognised in profit or loss include the following:
£
£
Interest on lease liabilities
30,155
26,883
PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2022
(Continued)
- 11 -
10
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the company and movements thereon during the current and prior reporting period.

ACAs
Tax losses
Retirement benefit obligations
Total
£
£
£
£
Liability at 1 December 2020
(40,639)
(144,176)
(5,185)
(190,000)
Deferred tax movements in prior year
Charge/(credit) to profit or loss
(10,731)
(52,923)
3,677
(59,977)
Asset at 1 December 2021
(51,370)
(197,099)
(1,508)
(249,977)
Deferred tax movements in current year
Charge/(credit) to profit or loss
14,183
-
1,955
16,138
Effect of change in tax rate - profit or loss
(16,222)
(62,242)
(477)
(78,941)
Asset at 31 December 2022
(53,409)
(259,341)
(30)
(312,780)

Deferred tax assets are expected to be recovered after more than one year.

11
Retirement benefit schemes
2022
2021
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
71,310
69,894

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

12
Share capital
2022
2021
2022
2021
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
6,500,002
6,500,002
6,500,002
6,500,002
13
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:

The auditor's report was unqualified.

PRESTIGE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2022
13
Audit report information
(Continued)
- 12 -
The senior statutory auditor was James King and the auditor was Pierce C A Limited.
14
Related party transactions

The company is exempt from disclosing related party transactions as they are with other companies that are wholly owned within the group.

2022-12-312021-12-01Mr J S PotterS EhrenreichN KinoryfalseCCH SoftwareiXBRL Review & Tag 2022.2028267932023-09-18No description of principal activityStatement on quality and completeness of information provided to auditors2023-09-18Opinion of auditors on entityJames KingPierce CA Limited028267932021-12-012022-12-31028267932022-12-31028267932021-11-3002826793core:ShareCapital2022-12-3102826793core:ShareCapital2021-11-3002826793core:RetainedEarningsAccumulatedLosses2022-12-3102826793core:RetainedEarningsAccumulatedLosses2021-11-30028267932020-11-30028267932020-12-012021-11-3002826793bus:Director12021-12-012022-12-3102826793core:Held-to-maturityFinancialAssets2021-12-012022-12-3102826793core:ComputerSoftware2021-11-3002826793core:DevelopmentCostsCapitalisedDevelopmentExpenditure2021-11-3002826793core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2021-11-3002826793core:ComputerSoftware2022-12-3102826793core:DevelopmentCostsCapitalisedDevelopmentExpenditure2022-12-3102826793core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2022-12-3102826793core:ComputerSoftware2021-11-3002826793core:DevelopmentCostsCapitalisedDevelopmentExpenditure2021-11-30028267932021-11-3002826793core:ComputerSoftware2021-12-012022-12-3102826793core:DevelopmentCostsCapitalisedDevelopmentExpenditure2021-12-012022-12-3102826793core:LandBuildingscore:LeasedAssetsHeldAsLessee2021-11-3002826793core:PlantMachinery2021-11-3002826793core:FurnitureFittings2021-11-3002826793core:MotorVehicles2021-11-3002826793core:LandBuildingscore:LeasedAssetsHeldAsLessee2022-12-3102826793core:PlantMachinery2022-12-3102826793core:FurnitureFittings2022-12-3102826793core:MotorVehicles2022-12-3102826793core:LandBuildingscore:LeasedAssetsHeldAsLessee2021-12-012022-12-3102826793core:PlantMachinery2021-12-012022-12-3102826793core:FurnitureFittings2021-12-012022-12-3102826793core:MotorVehicles2021-12-012022-12-3102826793core:ContinuingOperations2022-12-3102826793core:LandBuildingscore:LeasedAssetsHeldAsLessee2021-11-3002826793core:PlantMachinery2021-11-3002826793core:FurnitureFittings2021-11-3002826793core:MotorVehicles2021-11-3002826793core:CurrentFinancialInstruments2022-12-3102826793core:CurrentFinancialInstruments2021-11-3002826793core:Non-currentFinancialInstruments2022-12-3102826793core:Non-currentFinancialInstruments2021-11-3002826793core:WithinOneYear2022-12-3102826793core:WithinOneYear2021-11-3002826793core:AfterOneYear2022-12-3102826793core:AfterOneYear2021-11-3002826793core:AcceleratedTaxDepreciationDeferredTax2021-11-3002826793core:TaxLossesCarry-forwardsDeferredTax2021-11-3002826793core:RetirementBenefitObligationsDeferredTax2021-11-3002826793core:AcceleratedTaxDepreciationDeferredTax2022-12-3102826793core:TaxLossesCarry-forwardsDeferredTax2022-12-3102826793core:RetirementBenefitObligationsDeferredTax2022-12-3102826793bus:PrivateLimitedCompanyLtd2021-12-012022-12-3102826793bus:FRS1012021-12-012022-12-3102826793bus:Audited2021-12-012022-12-3102826793bus:Director22021-12-012022-12-3102826793bus:Director32021-12-012022-12-3102826793bus:FullAccounts2021-12-012022-12-31xbrli:purexbrli:sharesiso4217:GBP